"Pre-exposure prophylaxis (PrEP) is the most important concept in the [HIV] prevention field today," Robert Grant told the Infectious Disease Society of America at their annual meeting in San Diego.
The number of new HIV infections has fallen over the years – it declined by 39% from 2010 to 2023. But HIV’s devastating impact on global health persists. In 2023, 1.3 million people acquired HIV – ...
The landscape of HIV prevention has undergone a profound transformation with significant advancements in medical interventions and a deeper understanding of how the virus spreads. These developments ...
How Does Yeztugo Work to Prevent HIV? HIV is a virus that has a coating around it, which is called a capsid. In order for HIV to make copies of itself and spread within your body, it needs to get ...
June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections. Originally approved in 2012 as a treatment for people with HIV that no longer responded to ...
A vaccination with the drug lenacapavir offers an effective protection against a HIV infection, according to newly published research from the pivotal phase-three study "Purpose 2". The option to ...
According to UNAIDS, in 2024, about 40.8 million people around the world were living with the human immunodeficiency virus (HIV) — a virus that can lead to acquired immunodeficiency syndrome (AIDS) if ...
The U.S. Food and Drug Administration approved the second drug to help prevent HIV infections on Thursday. Descovy is a PrEP or pre-exposure prophylaxis drug, which means the drug is taken daily to ...
Gilead Sciences' new shot is a drug named lenacapavir, which was tested in two studies and reportedly eliminated HIV infections in high-risk patients. People have to test negative for HIV before they ...
The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it’s unclear how many in the U.S. and ...
Hilton Humphries does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...